相关实验视频

Updated: Sep 19, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

静脉内抗血管内皮生长因子剂和高血压之间的关联:一个元分析

Michael Balas¹, Aaditeya Jhaveri², Faran Khalid³

¹Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

|June 2, 2025

概括

内抗血管内皮生长因子 (VEGF) 药物和假注射具有类似的高血压风险. 这一元分析证实了可比的安全性概况,表明高血压风险不应该指导治疗选择.

科学领域:

眼科医生眼科眼科
心血管医学心血管医学
药理学药理学是指药理学的学科.

背景情况:

内抗血管内皮生长因子 (VEGF) 注射是各种视网膜疾病的标准治疗方法.
人们对与这些药物相关的潜在系统性副作用,包括高血压存在担忧.
不同抗VEGF药物之间对高血压风险的安全性数据的比较对于临床决策至关重要.

研究的目的:

系统地比较在接受静脉内抗VEGF药物和假注射的患者中高血压的发生率.
评估和比较不同静脉内抗VEGF药物之间的高血压风险.

主要方法:

从2005年1月到2023年8月,在主要数据库 (MEDLINE,EMBASE,Cochrane) 进行了全面的系统文献搜索.
随机临床试验 (RCT) 报告高血压是标准剂量静脉内抗VEGF药物的不良事件.
使用随机效应建模计算高血压发病率的风险比率 (RR) 和95%置信区间 (CI).

主要成果:

分析了20个涉及11,196名患者的RCT.
在不同药物中,高血压发病率略有变化:拉尼比祖马布 (6.6%),贝瓦齐祖马布 (4.2%),阿弗利柏塞特 (8.3%),布罗卢齐祖马布 (7.8%),法里西马布 (4.8%) 和假药 (7.7%).
在任何抗VEGF药物之间或与假注射相比,在高血压风险上没有发现统计学上显著的差异.

结论:

这一元分析表明,与假注射相比,内抗VEGF药物,包括拉尼比祖马布和阿弗利伯塞普,不会显著增加高血压的风险.
这些发现表明,在不同抗VEGF药物中,对高血压的系统安全性概况相似且有利.
内抗VEGF治疗的临床选择不应该受到高血压风险方面的影响.

更多相关视频

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

Published on: January 22, 2020

相关概念视频

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Hypertension I: Introduction

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...